Devonian Health Group Inc. (CVE:GSD – Get Free Report)’s stock price fell 23.5% on Saturday . The stock traded as low as C$0.09 and last traded at C$0.13. 119,000 shares traded hands during mid-day trading, an increase of 588% from the average session volume of 17,288 shares. The stock had previously closed at C$0.17.
Devonian Health Group Stock Down 23.5%
The company’s 50 day moving average price is C$0.16 and its two-hundred day moving average price is C$0.17. The company has a current ratio of 1.07, a quick ratio of 7.82 and a debt-to-equity ratio of 16.36. The stock has a market cap of C$19.27 million, a P/E ratio of -4.64 and a beta of 0.67.
Devonian Health Group Company Profile
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics.
Further Reading
- Five stocks we like better than Devonian Health Group
- What is the NASDAQ Stock Exchange?
- 3 Overlooked Value Stocks Set to Surge as Rates Drop
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy
- Profitably Trade Stocks at 52-Week Highs
- After the Fed’s Rate Cut, PNC Could See a Mortgage Refinance Boom
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
